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RUNNING TITLE: Adipose tissue functions in patients with LPIN1 mutations.	
 
ABBREVIATIONS: PAP: phosphatidic acid phosphatase; TAG: triacylglycerols; PL: polar lipids; PA: 
phosphatidate; WAT: white adipose tissue; FAO: fatty acids oxidation; TLC: thin layer chromatography; LD: 
lipid droplets; FA: unesterified fatty acids; GC-FID: gas chromatography-flame ionization detector; LCFA: long-
chain fatty acids; HDF: human dermal fibroblasts; GM: growth medium; DM: differentiation medium; DXM: 
dexamethasone; IBMX:  isobutylmethylxanthine; MSC: mesenchymal stem cells; SREBP1: Sterol regulatory 
element-binding protein 1; PPAR: Peroxisome proliferator-activated receptors; PGC1A: Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha; NFATc4: Nuclear factor of activated T-cells, 
cytoplasmic 4; VCAM-1: vascular cell adhesion molecule 1 (or cluster of differentiation 106, CD106); MCAM: 
melanoma cell adhesion molecule (or cluster of differentiation 146, CD146); ITGA11: integrin alpha-11; MME: 
neprilysin or membrane metallo-endopeptidase (or cluster of differentiation 10, CD10); DPP4: dipeptidyl 
peptidase-4 (or cluster of differentiation 26, CD26); FASN: fatty acid synthase; LPP: lipid phosphate 
phosphatase; SGBS: Simpson-Golabi-Behmel syndrome. 
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ABSTRACT 
Lipin-1 is a Mg2+-dependent phosphatidic acid phosphatase (PAP) that in mice is necessary for normal 
glycerolipid biosynthesis, controlling adipocytes metabolism and adipogenic differentiation. Mice carrying 
inactivating mutations in the Lpin1 gene display the characteristic features of human familial lipodystrophy. 
Very little is known on the roles of lipin-1 in human adipocyte physiology. Apparently fat distribution and 
weight is normal in humans carrying LPIN1 inactivating mutations, but a detailed analysis of adipose tissue 
appearance and functions in these patients has not been available so far. In this study, we performed a systematic 
histopathological, biochemical and gene expression analysis of adipose tissue biopsies from human patients 
harbouring LPIN1 biallelic inactivating mutations and affected by recurrent episodes of severe rhabdomyolysis. 
We also explored the adipogenic differentiation potential of human mesenchymal cell populations derived from 
lipin-1 defective patients. White adipose tissue from human LPIN1 mutant patients displayed a dramatic 
decrease in lipin-1 protein levels and PAP activity, with a concomitant moderate reduction of the adipocyte size. 
Nevertheless the adipose tissue develops without obvious histological signs of lipodystrophy and with a normal 
qualitative composition of the storage lipids. The increased expression of key adipogenic determinants such as 
SREBP1, PPARG and PGC1A shows that specific compensatory phenomena can be activated in vivo in human 
adipocytes under deficiency of a functional lipin-1. 
 
 
Keywords: 
Adipocytes, Adipose tissue, Gene expression, Lipodystrophies, Phosphatases/Lipid, Inborn errors of metabolism, 
Human lipids, Lipin-1, Adipogenic differentiation, Human fat lipid analysis. 
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INTRODUCTION  
Studies in vitro and in vivo using mouse models showed that the protein lipin-1, encoded by the gene 
Lpin1, is an enzyme necessary for normal glycerolipid biosynthesis, which is also able to control the adipocyte 
metabolism and adipogenic differentiation (1-7). Lipin proteins act as Mg2+-dependent phosphatidate 
phosphatases (PAP) that catalyze the dephosphorylation of phosphatidate (PA) to diacylglycerol (DAG), a direct 
precursor of triacylglycerols (TAG) and polar lipids (PL), such as phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) (8-10). Although lipin-1 does not have a DNA-binding motif, it is able to translocate 
to the nucleus of hepatocytes and adipocytes, where it can act as a transcriptional co-regulator (3, 11-14), 
interacting with PGC1α/PPARα and PPARγ, modulating their transcriptional activity and regulating 
adipogenesis, fatty acids oxidation (FAO) and the expression of key components of the mitochondrial respiratory 
chain (11-13, 15). Accordingly, lipin-1 deficient mice exhibit reduced expression of hepatic PPAR-regulated 
genes and impaired FAO activity (13, 16, 17). The effects of lipin-1 on transcription do not apparently require 
lipin-1 PAP activity, demonstrating that the enzymatic activity of lipin-1 can be functionally separated from its 
ability to co-regulate the transcription (11-13, 18). Moreover, lipin-1 has also been implicated in the modulation 
of pro-inflammatory responses both repressing NFATc4 activity and downstream cytokine production in the 
adipocytes (15) and positively controlling the production of pro-inflammatory factors during macrophage 
activation (19, 20). 
Lpin1 fatty liver dystrophic (fld) mice, i.e. Lpin1(fld/fld) deficient mice, carrying spontaneous inactivating 
mutations in the Lpin1 gene, show the characteristic features of the human congenital lipodystrophy (1-3, 7). 
This condition consists of a group of genetic disorders characterized by severe loss of body fat, associated with 
metabolic disturbances such as fatty liver, hypertriglyceridemia and insulin resistance (21). The absence or 
decreased levels of PAP activity in the white adipose tissue (WAT) of the Lpin1(fld/fld) mice as well in the WAT 
of other mouse or rat models without a functional lipin-1, result in dysregulated TAG biosynthesis, with the 
subsequent accumulation of PA (2, 5, 7, 14, 16, 22-25). The lipodystrophic lipin-1-deficient mouse models are 
characterized by: i) an impaired maintenance of the mature adipocytes, with a severe reduction in TAG storage 
and a consequent severe reduction (about 80%) of the fat body mass; ii) the presence of abnormal adipocytes, 
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with multilocular lipid droplets; iii) an impairment in adipogenic differentiation, with an important increase in 
the presence of immature adipocytes in the WAT (5, 7, 14). The rat model with a dominant negative mutation in 
the Lpin1 gene (the Lpin11Hubr rats) presents a milder but analogous form of lipodystrophy, characterized by 
impaired expression of key transcriptional adipogenic factors such as PGC1α and PPARα (24). Unexpectedly, 
the Lpin1(fld/fld) mouse does not show defects in TAG synthesis or β-oxidation in the heart where lipin-1 provides 
about 80% of the PAP activity and in this case the presence of the paralogues lipin-2 or lipin-3 appears to 
compensate for the absence of lipin-1 (25). 
The accumulated evidence from observations in lipin-1 deficient rodents models presents a 
lipodystrophic phenotype, together with data showing that lipin-1 is involved in the adipogenesis in vitro (3, 4, 6, 
26). The observations that the gene encoding for lipin-1 is prevalently expressed in adipose tissue in human 
beings and mouse (9), make LPIN1 a top-rank candidate for human lipodystrophy. However, we and other 
investigators have reported that the presence of LPIN1 inactivating mutations in human patients leads to a 
dramatic and peculiar skeletal muscle-related pathological phenotype, which consists of recurrent and severe 
episodes of rhabdomyolysis (i.e. massive breakdown of the skeletal muscle fibers), without any evident 
involvement of the adipose tissue (27-29). Consistent with the prevailing human phenotype, the absence of lipin-
1 can induce a failure in the maintenance of muscle integrity under special conditions of metabolic stress in 
Lpin1(fld/fld) mice (30).  
 The role of lipins in human adipogenesis and human adipose tissue functions is still undefined. Recently 
it was shown in human Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cell line (an in vitro cell 
model for studies of human adipocyte differentiation) that lipin-1 is progressively induced during adipogenesis 
and that depletion of lipin-1 by siRNA, leads to depletion of about 95% of the PAP activity and to a significant 
reduction of the key adipogenic transcription factors PPARG and SREBP1 (31). Nevertheless, the SGBS cell 
line differentiated normally and accumulated neutral lipids under deficiency of lipin-1, supporting the hypothesis 
of the existence of alternative pathways for TAG synthesis in human adipocytes subjected to conditions of 
repressed lipin-1 expression (31).  
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 In-depth biochemical, histological and biological analyses of adipose tissue derived from lipin-1 
defective patients have not been performed so far. In spite of the absence of obvious signs of adipose tissue loss 
and lack of the metabolic disturbances usually associated with lipodystrophy, we cannot yet exclude that human 
lipin-1 defective individuals (as in rodents) manifest some failures of adipose tissue homeostasis. To clarify the 
effects of lipin-1 deficiency on human adipose tissue, we performed a systematic analysis of WAT biopsies 
derived from patients carrying biallelic LPIN1 inactivating mutations. Also, to assess the possible role played by 
lipin-1 in human adipogenesis, we triggered the adipogenic differentiation potential of primary mesenchymal 
cells derived from lipin-1 defective patients.  
Our analysis established that the adipose tissue from human lipin-1 defective patients is characterized by 
a marked decrease in lipin-1 protein levels and PAP activity, with a concomitant moderate reduction of the 
adipocyte size. However, WAT in lipin-1 defective human individuals develops without detectable 
histopathological signs of lipodystrophy and with an apparently normal qualitative composition of stored lipids. 
The increased expression of key adipogenic determinants such as SREBP1, PPARG and PGC1A shows that a 
specific compensatory phenomenon can be activated in vivo in human adipocytes in the presence of depleted 
lipin-1 expression. 
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MATERIALS and METHODS 
 
Materials. All reagents were purchased from Sigma-Aldrich, unless otherwise specified. 
 
Patients and healthy control individuals. All the patients were clinically and genetically characterized, and 
they suffered from recurrent episodes of rhabdomyolysis (27, 28, 29, 32). When fat biopsies were taken, the 
patients were apparently in good health, fully compensated, and not suffering of episodes of rhabdomyolysis for 
several months. Table 1 summarizes the characterization of the patients and healthy control individuals used in 
the present study. 
 
Biopsy method. Subcutaneous WAT samples biopsies were obtained from the brachial region (deltoid region) 
of the lipin-1 defective patients, or from the dorsal region for the control individuals. Only in Fig. 4 two WAT 
control biopsies were from breast adipose tissue from healthy adult individuals (aged 53 and 56) subjected to 
reduction mastoplasty. Otherwise, the collection of the WAT samples required a <0.5 cm scalpel incision, and 
subsequent collection of the biopsy, using a 14-Gauge needle. Adipose tissue samples were rapidly rinsed in 
PBS and immediately analysed or frozen. This work has been approved by the Hôpital Necker-Enfant Malades 
Ethical Committee after declaration to the Département de la Recherche Clinique et du Développement 
(Assistance Publique, Hôpitaux de Paris, France) and informed consent was provided (by a parent or guardian 
for each child). Breast adipose tissue (controls B1 and B2 in Fig. 4) was obtained with approval of the University 
of Alberta Health Research Ethics Board ID Pro00018758, with written informed consent. 
 
Electron microscopy. WAT biopsies (~8 mm3) were fixed for 16 h at 4°C in 2.5% glutaraldehyde in 0.1 M 
Sorensen's buffer, pH 7.4. Samples were rinsed in 0.2 M cacodylate buffer, pH 7.4, and subsequently post-fixed 
with 2% osmium tetroxide/1.5% potassium ferrocyanide in 0.2 M cacodylate buffer, pH 7.4, for 45 min at room 
temperature. Samples were then rinsed with distilled water, dehydrated in ethanol and embedded in EMbed 812 
epoxy resin (LFG Distribution) at 60°C for 48 h. Semi-thin sections (1 µm-thickness) were cut with an EM-UC7 
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ultramicrotome (Leica), colored with 1% methylene blue/1% Azur B and observed with an Olympus AX-60 
microscope (Olympus) equipped with a QImaging QIClick digital CCD camera (QImaging, Surrey, BC, 
Canada). Thin sections (60 nm-thickness) were cut and counterstained with uranyl acetate and observed with a 
Jeol JEM 1400 microscope (Jeol, Croissy sur Seine, France) operated at 120 KeV and equipped with a Gatan 
Orius Camera (Gatan, Pleasanton, CA, USA). 
 
Immunohistofluorescence. Adipose tissue biopsies (WAT) were fixed for 12-16 h at room temperature in 4% 
paraformaldehyde and embedded in paraffin. Five µm sections were cut at 50 µm intervals and mounted on 
charged glass slides. Paraffin was removed with xylene, and slides were stained for the expression of perilipin, 
using an anti–perilipin-1/PLIN1 antibody (Progen) as described (33). Adipose tissue sections were stained with 
DAPI, prior to mounting them using the mounting medium Fluoromount-G (SouthernBiotech). The total 
numbers of nuclei and adipocytes were counted in 5 microscopic fields for each biopsy. The adipose tissue 
cellular composition was then determined for each histological sample as the total number of adipocytes (in 
which perilipin-1 decorates an unilocular lipid droplet, occupying the entire cell volume) divided by the total 
number of nuclei (DAPI positive). 
 
Adipocytes diameter measurements. Fat biopies (~8 mm3) were fixed as indicated in the “Electron 
Microscopy” section (see above); semi-thin sections (500 nm-thickness) were cut with an EM-UC7 
ultramicrotome (Leica), colored with 1% methylene blue/1% Azur B and observed with an AX-60 microscope as 
indicated above. Adipocyte diameters (expressed in µm) of at least 100 mature adipocytes in each section were 
measured on microscopic images, using Image J software. The cumulative distribution function (CDF) of the 
adipocytes diameters was estimated statistically by the empirical cumulative function (ECDF) (see Fig. 3). The 
measured adipocytes diameters for each experimental individual or group were divided into arbitrary classes, 
with ~16 µm intervals. The Kolmogorov-Smirnov test was used as a non-parametric statistic to test the equality 
of CDFs, i.e. testing the null hypothesis that the samples were drawn from the same population (described by the 
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corresponding CDF). All statistical analyses, including graphical representations and exploratory statistics, were 
performed using the open source software R, release 3.2.2 “Fire safety” (34). 
 
Enzymatic activity for PAP. An enzymatic assay for PAP was performed as described in (25). Briefly, adipose 
tissue was homogenized in sucrose buffer consisting of 250 mM sucrose, 0.6 mM dithiothreitol (DTT) and 
protease inhibitor cocktail, followed by centrifugation to collect the infranatant in which PAP activity was 
measured. Each sample was assayed in a total volume of 100 µl consisting of 100 mM Tris/HCl (pH 7.4) 
containing 0.6 mM DTT, 1.5 mM MgCl2, 2 mg/ml fat-free BSA, protease inhibitor cocktail, 30 nM microcystin-
LR, 0.6 mM phosphatidate (PA) labelled with [3H]palmitate {[9,10-3H(N)]-palmitic Acid, PerkinElmer}, 1 mM 
EDTA/EGTA, 0.4 mM phosphatidylcholine, and 200 µM tetrahydrolipstatin to block lipase activity. Parallel 
measurements were performed in the absence of Mg2+ and in the presence of 8 mM N-ethylmaleimide (NEM) to 
determine the contribution from lipid phosphate phosphatase (LPP) activity. The diacylglycerol that was formed 
was extracted in 2 ml of chloroform-methanol (19:5, v/v) containing 0.08% olive oil as carrier. Activated 
alumina was added to remove the unreacted PA and any liberated [3H]palmitate from the chloroform phase. The 
chloroform phase was dried, and the radioactivity determined. PAP activity was calculated by subtracting the 
NEM-insensitive LPP activity from the total phosphatidate phosphatase activity. Each sample was assayed at 
three different protein concentrations to ensure a proportional response. 	
Western blotting analysis for lipin-1. Adipose tissue was homogenized in RIPA buffer followed by 
centrifugation. The infranatant was collected and four volumes of ice-cold acetone were added to precipitate 
protein. After centrifugation at 12,000xg for 10 min, protein precipitations were washed with one volume of ice-
cold acetone and proteins were dried at room temperature. Protein precipitations were resuspended in RIPA 
buffer. Sixty µg of protein was loaded for PAGE (25) and probed with anti-lipin1/LPIN1 antibody (Abcam) or 
with an anti tubulin antibody as a loading control. Blots were analyzed by Li-cor C-DiGit Blot imaging scanner. 
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Lipid analysis. WAT (about 15-20 mm3) were extracted in 2 ml of chloroform/methanol 2:1, (v/v) using a glass 
Potter-Elvehjem homogenizer with a PTFE pestle. 500 µl of 1% perchloric acid was added and the extracted 
suspension vortexed for 30 s. After centrifugation, the organic phase was isolated, and the aqueous phase further 
extracted with 2 ml of chloroform/methanol 2:1 (v/v). The two organic phases were pooled in a glass test tube 
(test tube A) and evaporated to dryness. A fully quantitative procedure to efficiently separate the less abundant 
total PL from the highly prevalent TAG from total lipid extracts from each fat biopsy was adapted from a 
previously described two-phase hexane/(ethanol-water) extraction method (35).  Briefly, a stock biphasic solvent 
system was prepared by mixing equal volumes of hexane and an aqueous ethanol solution (13% water, 87% 
ethanol, by vol.). 4.5 ml of the upper phase and 1.5 ml of the lower phase of the biphasic solvent system were 
add to the test tube A, containing the dried extracted lipids, and mixed thoroughly. The extracted lower phase 
from the test tube A was transferred to a second test tube (B) containing 4.5 ml of pre-equilibrated upper phase 
stock solvent system. 1.5 ml of the lower phase of the stock solvent system was added to the test tube A. Test 
tubes A and B were mixed thoroughly and after equilibration the lower phase of the test tube B was isolated, and 
the lower phase of the test tube A was transferred to the test tube B. The above procedure was repeated six times. 
The combined upper phases (i.e. 8 times 1.5 ml) represented the ethanolic phase, prevalently containing PL (Fig. 
3), and the remaining upper phases from test tube A and B represented the hexane phase #1 and the hexane 
phase #2, respectively, prevalently containing neutral lipids (Fig. 3). The different extracted phases were 
evaporated to dryness and re-dissolved in 4 ml (for the hexane phase #1) or 100 µl (for the hexane phase #2 and 
the ethanolic phase) of chloroform/methanol (2:1, v/v). 100 µl of the hexane phases and of the ethanolic phase 
were analyzed by one-dimensional high performance TLC on silica gel 60 (Merck) using hexane/diethyl 
ether/acetic acid (90:15:2, v/v/v) as mobile phase for neutral lipid separation (36, 37) and using chloroform, 
methanol, water, ammonia 25% (60:34:4:2, v/v/v/v) as mobile phase for the polar lipid separation (38). The 
lipids were then located by spraying the TLC plates with 0.001% (w/v) primuline in 80% acetone, followed by 
Imaging (ChemiDoc, Bio-Rad).  
 The silica gel zones corresponding to TAG and PL were scrapped from the TLC plates and the acyl 
chains analyzed by gas-chromatography (GC-FID).  The spot scrapped were added to 1 ml of methanol/2.5% 
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H2SO4 containing 5 µg of heptadecanoic acid methyl ester. After maintaining the lipids in the mixture at 80◦C for 
1 h, 1.5 ml of water was added and FA methyl esters extracted using 0.75 ml of hexane. Separation of FA 
methylesters was performed by GC (Hewlett–Packard 5890, series II) on a 15 m×0.53 mm Carbowax column 
(Alltech Associates, Deerfield, IL) by flame-ionization detection (GC-FID). The retention times of FA 
methylesters were determined by comparison with standards, and they were quantified using heptadecanoic acid 
methyl ester as a standard (39). 
 
Isolation of dermal fibroblasts. Human primary dermal fibroblasts populations were established from biopsy 
specimens obtained from the brachial region (deltoid region) of lipin-1 defective patients or from the dorsal 
forearm region for the controls individuals. Tissue biopsies were dissociated enzymatically in 0.25% collagenase 
type I and 0.05% DNase in DMEM with 20% foetal bovine serum (FBS) overnight, at 37°C. Primary fibroblast 
cultures were established in 25-cm2 culture flasks in DMEM, supplemented with 20% fetal calf serum (FCS) and 
2 mM glutamine. Monolayer cultures were maintained at 37°C in 10% CO2 until about 70% confluence. Cells 
were then passaged and used for experiments.  
 
Adipogenic differentation of human primary dermal fibroblasts populations. Human primary dermal 
fibroblasts were plated in Growth Medium (GM) containing DMEM + 2 mM glutamine and 10% FCS (all from 
Life Technologies), on culture dishes. After two days of post-confluence (which was considered as day 0), cells 
were shifted in adipogenic differentiation medium (DM) containing DMEM + 2 mM glutamine, 10% FCS, 500 
nM bovine insulin, 500 nM dexamethasone, 500 µM 3-Isobutyl-1-methylxanthine and 50 µM indomethacin or in 
control medium (DMEM + 2 mM glutamine, containing 10% FCS). Every two days the DM or the control 
medium was replaced, and at 4, 8 and 12 days cells were collected for the RNA extraction and for further 
analysis. 
 
RNA isolation, RT (reverse transcription) and real time PCR. Human primary dermal fibroblasts cells were 
washed with ice-cold PBS and total RNA was extracted using the TRIzol reagent (Life Technologies). Human 
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fat biopsies (WAT, about 5-10 mm3) were rinsed in cold PBS and immediately frozen in liquid nitrogen; 
subsequently biopsies were homogenized in about 500 ml of TRIzol Reagent using a glass Potter-Elvehjem 
homogenizer with a glass pestle. The homogenate was subjected to centrifugation at 12,000xg for 8 min at 4°C. 
The pellet and the top fat layer were discarded whereas the aqueous phase was subjected to standard TRIzol 
protocol according to manufacturer’s instructions, for total RNA purification. Digestion of contaminating 
genomic DNA was performed with DNA-free DNase treatment (Ambion). First strand cDNA was generated 
using a kit with random primers (High Capacity cDNA Reverse Transcription kit, Applied Biosystems) from 
1 µg of total RNA. Newly synthesized cDNA was diluted 5-fold in DNase-free water, and 5% of this cDNA was 
used in each real-time PCR assay, using a 7500 Real Time PCR System (Applied Biosystems) (40, 41). The 
standard curve method was used to calculate the relative mRNA levels for each transcript examined and human 
was used as a reference to normalize the results. The sequence (5’to 3’) of the specific primers used for the 
SYBR Green quantification of the mRNA (Power SYBR Green PCR Master Mix, Applied Biosystems) were: 
MME, human membrane metallo-endopeptidase: forward primer: CCTCACCATCATAGCTGTGACAA; reverse 
primer: TGACTTGCAAATACCATCATCGT. MCAM, human melanoma cell adhesion molecule: forward primer: 
CCTGGACTTGGACACCATGAT; reverse primer: ACGTCAGACACATAGTTCACCAGTAGT. VCAM1, human 
vascular cell adhesion molecule 1: forward primer: CAAAGGCAGAGTACGCAAACAC; reverse primer: 
GCTGACCAAGACGGTTGTATCTC. ITGA11, human integrin alpha 11: forward primer: 
GCACCCCATTTCCAAACAAC; reverse primer: ACCGCCTCTCATCCATGGT. DPP4, human dipeptidyl-peptidase 
4: forward primer: CAGTCACCAATGCAACTTCCA; reverse primer: ACAAGTAGTGATCCCCTATCAACATAGA. 
PPAR-γ, human peroxisome proliferator-activated receptor gamma (PPARG): forward primer: 
GGGCGATCTTGACAGGAAAG; reverse primer: CCCATCATTAAGGAATTCATGTCAT. FASN, human fatty acid 
synthase: forward primer: CAGACGAGAGCACCTTTGATGAC; reverse primer: 
CAGGTCTATGAGGCCTATCTGGAT. PGC1-α, human peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha (PPARGC1A): forward primer: ACCCAGAACCATGCAAATCAC; reverse primer: 
GCTCCATGAATTCTCAGTCTTAACAA. LPIN1, human lipin-1: forward primer: TGAAAAGGGGCTCTGTGGAC; 
reverse primer: ACTACAGAGCTGCTTGACGG. LPIN2, human Lipin-2: forward primer: 
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GGTCCCCTTTAGAGACCACCTATC; reverse primer: CACCTCCAGCTCTGAATCACTCTT. ACTB, human actin 
beta: forward primer: CTGGCACCCAGCACAATG; reverse primer: CCGATCCACACGGAGTACTTG. SREBF1, 
human sterol regulatory element binding transcription factor 1: forward primer: 
GCTGTCCACAAAAGCAAATCTCT; reverse primer: TCAGTGTGTCCTCCACCTCAGT. 
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RESULTS 
  
Histomorphometrical and ultrastructural analyses of human adipose tissue in patients carrying biallelic 
LPIN1 mutations. 
 Mice carrying inactivating mutations of the Lpin1 gene are characterized by manifested lipodystrophy 
features, with a severe reduction of total fat mass, presence of abnormal adipocytes with multilocular lipid 
droplets and a significant increase of immature adipocytes in the adipose tissue (2, 7, 14). The role of lipins in 
human adipogenesis is still undefined. To investigate the consequences of the deficiency of lipin-1 in human 
adipogenesis, we examined fat biopsies from human patients carrying biallelic inactivating mutations in the 
LPIN1 gene, to search for signs of defects in the histological structure, indicative of lipodystrophy. 
According to previous studies, two divergent histopathological subsets can be observed in congenital or 
acquired forms of human lipodystrophy (42). One form of lipodystrophy is characterized histologically: i) by 
small adipocytes, embedded in hyaline connective tissue, ii) by the presence of a myxoid stroma with numerous 
capillaries, and iii) by a very scarce infiltration of inflammatory cells (42). The second type of human 
lipodystrophy is characterized instead by a distinctive "inflammation of the fat", with the hallmark presence of 
focal lymphocytes, histiocytes and plasma cells, but showing normal-appearing adipocytes and normal 
vasculature (42). In all cases lipodystrophic adipose tissue can be recognized histologically by alteration in the 
proportions of mature fat cells to non-fat cells (33). 
Mature adipocytes (and the shape of the lipid droplets) were identified on histological adipose tissues 
sections, based on their characteristic perilipin-staining of the monolocular lipid droplet ((43) and Fig. 2). 
Perilipin-1 was abundantly expressed in mature adipocytes, where it localized at the surface of the intracellular 
lipids droplets (LD) (43). Like in the normal controls, the histological and ultrastructural analyses of the human 
fat biopsies from lipin-1 defective patients did not show any evidence of histopathological features associated 
with lipodystrophy (Fig. 1 and 2). No manifest signs suggestive of hypoplastic development, inflammation, 
increased presence of stromal cells or perturbation of the morphology (i.e. increased presence of mixoid stroma, 
lobules of small adipocytes, or abnormal vasculature) were observed by histological and ultrastructural analyses 
of the adipose tissue from lipin-1 defective patients (Fig. 1 and 2).  
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We did not observe abnormal or multilocular lipid droplets (Fig. 2). Perilipin immunostaining of the 
lipid droplets was conserved, since it decorated unilocular LD occupying the entire cell volume of the adipocytes 
(Fig. 2). The ultrastructural analysis confirmed the full integrity of the LD membrane and structure in lipin-1 
defective patients (Fig. 1 C and F). 
We next assessed the ratio between the number of mature adipocytes (showing large perilipin-1-positive 
monolocular LD) and the number of cells (based on DAPI nuclei detection) in adipose tissue histological 
sections (Fig. 2). This enabled us to detect possible changes in the proportion between adipocyte and non-
adipocyte cells (including the stromal cells fraction). Significant decreased values in this ratio are indicative of 
adipose tissue infiltration by non-adipose cells, disclosing an inflammatory state or suggesting an hypoplastic 
development of the adipose tissue, which are are often observed in lipodystrophies (33). The ratio 
perilipin/DAPI was not significantly affected in human adipose tissue from patients carrying biallelic LPIN1 
inactivating mutations compared to normal control individuals (Fig. 2). This result indicates that adipose tissue 
from lipin-1 defective patients was not significantly hypoplastic or infiltrated with immature adipocytes and non-
adipocytic cells, including inflammatory cells. 
 Some forms of mild lipodystrophy are characterized by the presence of adipocytes with a reduced size 
(42), and this feature is symptomatic of a deficiency in accumulation of TAG in the LDs. We performed a 
semiautomated histomorphometric analysis of the diameter of the adipocytes in fat biopsies from normal 
controls and from patients harbouring LPIN1 inactivating mutations.  
 At first we proceeded to calculate exploratory statistics for the diameter of the adipocytes for the entire 
groups of controls and patients, suggesting a possible decrease in adipocyte diameter in patients when compared 
to the controls (Table 2 A). Subsequently, individual histogram representations of the adipocyte diameter 
distribution were built for both controls and patients, considering each individual separately (Fig. 3 A). 
Analogously, histograms of the adipocytes diameter distribution were also built for the entire group of the 
controls and the entire group of the patients (Fig. 3 B).  
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  The empirical cumulative distribution function (ECDF) of the adipocytes diameter was then calculated 
for the grouped controls versus the grouped patients (Fig. 3 C). The adipocyte size for the grouped patients (n=4) 
was significantly smaller compared to grouped normal controls (n=5), as statistically tested by the Kolmogorov-
Smirnov non-parametric test (KS-test) (Table 2 B and Fig. 3 C).  
  To minimize possible confounding effects of age on the adipocyte size, we also adopted a special 
statistical analysis: the ECDF of the adipocytes diameters were calculated for each patient and for the grouped 
controls, and the KS-test was applied to test the null hypothesis that the values observed on each patient were 
drawn from the same CDF of the grouped controls (see Table 2 B). Adipocyte sizes for three out of four patients 
studied (i.e., for patient 1, age 5; for patient 3, age 11; and for patient 4, age 47) were significantly smaller 
compared to grouped normal controls (see Table 2 B and Fig. 3 A).  
In conclusion, no significant signs of perturbation of the morphology, hypoplastic development or 
inflammation were observed in adipose tissue of patients carrying LPIN1 inactivating mutations. We found a 
significant (albeit moderate) reduction in adipocyte size. This latter observation indicates a slightly decreased 
capacity of fat accumulation in the LDs in the adipose tissue of patients harbouring biallelic LPIN1 mutations. 
However, we cannot exclude the possibility that the reduced adipocyte size might also depend on confounding 
factors, which are not fully controllable under our experimental conditions. 
 
Analysis of lipin expression levels and PAP activity in the adipose tissue of patients carrying biallelic 
LPIN1 mutations. 
 We also analysed the LPIN1 gene expression levels, the lipin-1 protein levels, and PAP activity in fat 
biopsies from human patients carrying LPIN1 biallelic inactivating mutations. The LPIN1 deleterious mutations 
lead to stop codons or internal deletions (see Table 1 and (27-29, 32)). Real-time PCR analysis showed 
significantly lower LPIN1 mRNA levels in the adipose tissue from patients compared with normal controls (Fig. 
6 D). This could depend on an intracellular instability of the mutated/truncated LPIN1 mRNA variants, which 
could be more rapidly degraded, compared to non-mutated (WT) LPIN1 mRNA (44). 
 by guest, on Novem
ber 2, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
17		
 WAT from patients carrying LPIN1 homozygous early stop mutations (p.Arg388X/p.Arg388X) or 
heterozygous LPIN1 mutations (p.Asn417LysfsX22/p.Glu766_Ser838del, i.e. an early stop mutation and a C-
terminal deletion), showed dramatically reduced the levels of lipin-1, without significant differences in lipin-1 
expression between homozygous and heterozygous mutant alleles (Fig. 4 A and B). This suggests that mRNA 
resulting from the LPIN1 3'-terminal deletion mutant alleles in the heterozygous patients is unstable. (29). 
 However, in none of the patients analysed was the apparent expression of lipin-1 completely abolished: a 
weak protein band of about 100 kDa was still recognized in both types of LPIN1 biallelic inactivating mutations 
(Fig. 4 A). On average, ~23% of the staining was still present in WB of WAT from patients carrying LPIN1 
mutations (Fig. 4 A and B). We hypothesize that it could correspond to lipin-2 since the anti-human lipin-1 
antibody that we used in the WB analysis can also weakly cross-react with the 98 kDa lipin-2 (results not 
shown). 
 All patients showed a similar dramatic impairment of PAP activity in their WAT with only ~13% of the 
PAP activity of the controls (Fig. 4 C). There were no significant differences in PAP activity between the 
homozygous and compound heterozygous alleles. This result shows that lipin-1 accounts for the majority PAP 
activity in human WAT, as expected. We also obtained previous evidence in primary myoblasts established from 
lipin-1 defective patients (29), that different LPIN1 mutant alleles (homozygous C-terminal deletion, 
homozygous early stop mutation, and heterozygous early stop mutation + C-terminal deletion) are all associated 
with a severe reduction of PAP activity, although this was not totally abolished (29). 
We hypothesized that lipin-2 and lipin-3 can contribute to the residual PAP activity in lipin-1 defective 
patients (9, 45). Therefore, we explored the possibility of a compensatory overexpression of LPIN2 or LPIN3 in 
human adipose tissue in presence of deleterious mutation of LPIN1 (9, 45). LPIN2 mRNA expression levels 
were not significantly modulated in lipin-1 defective patients compared to controls (Fig. 6 E). Moreover, LPIN3 
mRNA was always undetectable by real-time PCR in the adipose tissue biopsies of both patients and controls 
(results not shown). This is consistent with previous observations, showing that LPIN3 is selectively expressed 
in intestine, platelets, B-lymphocytes, and in a subset of neuronal cells, but virtually absent in other tissues, like 
adipose and muscle (Ref. (9) and see the BioGPS gene annotation web portal (46)).  
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Altogether these results suggest that: i) lipin-1 defective patients had severely reduced LPIN1/lipin-1 
expression and PAP activity; ii) lipin-1 accounts for the majority PAP activity in human WAT; iii) the 
expression of LPIN2 potentially appears to provide the residual PAP activity in lipin-1-deficient patients; and iv) 
there appeared to be no compensatory mechanisms that increase the expression of LPIN2 or LPIN3. 
 
Qualitative analysis of lipids in human adipose tissue from lipin-1 defective patients. 
 To further understand the functions of lipin-1 in human adipose tissue, we explored the qualitative 
composition of the storage lipids in human WAT biopsies from lipin-1 defective patients. 
 A quantitative (i.e. absolute) determination of the lipid content in the adipose tissue biopsies was 
difficult, due to lack of tissue homogeneity among different biopsies. In fact, each minute biopsied adipose 
sample was characterized by a variable and uncontrollable intrinsic presence of stromal, connective and vascular 
tissues, which makes normalization based on the mass of protein or the total mass of each biopsy impractical. A 
rigorous compromise in our analysis was to quantify the relative abundance of TAG and PL in the total lipid 
extracts from each biopsy (Fig. 5 E and (39)). 
 We applied a fully quantitative procedure to separate total PL and TAG from total lipid extracts derived 
from each fat biopsy (35). Representative TLCs for the extracted lipid fractions are shown for a patient and a 
control individual in Fig. 5 A-D.  
 Our qualitative analysis of the lipids in human WAT showed that: i) inactivating mutations in the LPIN1 
gene which severely compromise the PAP activity, do not significantly affect the relative proportions between 
TAG and PL, compared to normal controls (Fig. 5 E), and do not apparently affect the general qualitative lipid 
landscape, as shown by TLC analysis (Fig. 5 A-D). ii) as a general physiological observation, the LCFATAG 
exceed, on average, about 2,000 times the LCFAPL (Fig. 5 E), and the ratio LCFATAG/LCFAPL offers a clear 
estimate of the prevalence of TAG over PL in human WAT. iii) storage lipids from lipin-1 defective patients do 
not show abnormal accumulation of unesterifed FA (Fig. 5 A-D). iv) in TAG extracts from lipin-1 defective 
patients, the impairment of lipin-1 does not significantly affect the relative abundance of unsaturated and 
saturated long chain fatty acids (LCFATAG 16:0, 16:1, 18:0, 18:1 and 18:2), compared to normal control 
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individuals (see analysis in Table 3). 
 As mentioned before, the absence or decreased levels of PAP activity in the WAT in mouse or rat 
models without a functional lipin-1, results in dysregulated TAG biosynthesis, with the subsequent accumulation 
of PA (2, 16, 23, 24). Because the very limited amount of the starting WAT biopsies, and the intrinsic low levels 
of PA, using an enzymatic method (47) or direct TLC methods (38) we could not to accurately determine the 
abundance of  this short-living phospholipid (Fig. 5 B and D). 
 In conclusion, there was a normal qualitative lipid composition of human WAT from lipin-1 defective 
patients. 
 
Expression analysis of key adipogenic genes in fat biopsies from lipin-1 defective patients. 
 We performed gene expression analysis in the adipose tissue from lipin-1 defective patients, with 
emphasis on some pivotal determinants and regulators of adipogenesis, namely SREBF1 (SREBP1), PPARG 
(PPARγ) and PGC1A (PGC-1α), which have been involved in the maintenance of the mature adipose phenotype 
and are potential lipin-1 transcriptional targets (Fig. 6 A-C) (48-50).  
 Unexpectedly, we found that fat biopsies from lipin-1 defective patients express significantly higher 
levels of two key transcription factors regulated by CCAAT/enhancer binding proteins, PPARG, SREBF1 and of 
PGC1A, compared with normal controls (Fig. 6 A-C).  SREBP1 and PPARγ have an established role in FA 
biosynthesis and adipocyte differentiation (49), are subjected to transcriptional co-activation by PGC-1α (48, 
50), and their impairment has been directly associated to congenital forms of lipodystrophy (51, 52). Therefore, 
our observations indicate that a specific compensatory phenomenon can be activated in vivo in human 
adipocytes in the presence of depleted lipin-1 expression.  
 
Induction of adipogenic differentiation in human dermal fibroblasts populations isolated from patients 
carrying biallelic LPIN1 mutations. 
 by guest, on Novem
ber 2, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
20		
 Lipin-1 plays an established role in the regulation of mouse adipogenic differentiation (3, 7, 14, 53), and 
primary mouse embryonic fibroblasts derived from lipin-1-deficient mice [Lpin1(fld/fld) mice] display a severely 
impaired adipogenic differentiation (3).  
In this study, we established primary human dermal fibroblasts (HDF) populations from lipin-1 defective 
patients and from control individuals. It has been shown that HDF populations possess a mesenchymal potential, 
and can be committed to adipogenic differentiation in the presence of an appropriate differentiation medium 
(DM) containing a combination of insulin, glucocorticoids and pharmacological compounds that increase the 
intracellular cAMP (54, 55). Previous investigations showed variable degrees of mesenchymal potential in HDF 
populations isolated from different individuals (56, 57), and this likely depends on the variable fraction of 
mesenchymal stem cells (MSC) in the diverse HDF cellular preparations. 
Consistently, as shown in Fig. 7, we observed that all the different HDF populations (that we isolated 
from patients or controls, see Table 1) expressed significant levels of genes encoding the MSC-specific surface 
markers [VCAM-1 (CD106), MCAM (CD146) and ITGA11 (56, 57, 58)], even if there was an ample 
heterogeneity in the expression levels of these genes between the various HDF populations (Fig. 7). The same 
primary HDF populations also expressed MME (CD10) and DPP4 (CD26), which are considered to be 
fibroblast-specific cell surface markers (Fig. 7) (58). Therefore, all the HDF populations we isolated could 
potentially exhibit a mesenchymal differentiation capacity, and be potentially committed to adipogenic 
differentiation. 
 All of the HDF populations derived from lipin-1 defective patients or normal control individuals, when 
exposed to adipogenic DM, progressively expressed PPARG, FASN and PGC1A (Fig. 8), which are key markers 
of adipogenic differentiation (48, 49, 50, 59). This increased expression of adipogenic markers during the 
progression of the differentiation was associated with a late and sporadic (i.e. in less than 10% of the confluent 
cells) accumulation of intracellular lipid droplets, in the late differentiation times (later than 8 days in DM, 
results not shown). 
These results show that the impairment of lipin-1 in primary human pre-adipogenic cell populations does 
not affect the induction of key transcriptional events that characterize the multistep process of adipogenic 
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differentiation (Fig. 8). They also show that there was a significant gene expression of the bona fide-considered 
MSC-specific markers (such as VCAM-1, MCAM and ITGA11) in primary HDF populations, which could be a 
sufficient predictive indicator of the adipogenic potential (57, 58). Further experiments are required to assess 
whether the expression of this cluster of MSC-specific markers can also outline the mesenchymal multipotency 
of primary HDF populations. 
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DISCUSSION 
 We used human fat biopsies from patients carrying inactivating mutations in the LPIN1 gene in both 
alleles to explore whether impairment of lipin-1 is associated with metabolic, developmental or histopathological 
defects that can be ascribed to lipodystrophy or adipose tissue deficiencies. Acquired or congenital 
lipodystrophies are a clinically and genetically heterogeneous group of metabolic disorders, characterized by 
either a partial or a generalized lack of adipose tissue (51, 52, 60). Lipodystrophies are typically associated with 
dyslipidemia, fatty liver, insulin resistance, diabetes and cardiovascular disease (21, 60, 61). Some underlying 
genetic defects observed in the lipodystrophies are directly related to adipocyte development such as mutations 
in the gene encoding for the transcription factor PPARγ (51). Mutations in the gene associated with glycerolipid 
synthesis such as AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2, also known as BSCL1) are 
associated with the congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome. This is a very 
severe form of generalized human lipodystrophy, characterized by the virtual absence of adipose tissue and a 
severe insulin resistance (21). AGPAT2 encodes an enzyme located within the endoplasmic reticulum (ER) that 
converts lysophosphatate to phosphatate, the second step in de novo phospholipid biosynthesis. Mutations in the 
gene known as BSCL2, are involved in the type 2-Berardinelli-Seip congenital lipodystrophy (62). Interestingly, 
BSCL2 encodes seipin, a transmembrane protein localized to the ER which can bind lipin-1 (63). 
LPIN1 is a top-rank candidate gene for human congenital lipodystrophy. Lipin-1 dephosphorylates PA to 
DAG, a common precursor for TAG and PL synthesis (64), acting in the metabolic pathway immediately 
downstream of AGPAT2. Therefore, the gene products of AGPAT, LPIN1 and BSCL2 are closely functionally or 
physically associated, explaining how mutations in each of these genes can be directly correlated to 
lipodystrophy. The Lpin1 gene is prevalently expressed in white and brown adipose tissue, and in skeletal and 
cardiac muscles, that are all tissues characterized by active TAG synthesis and/or by a high capacity β-oxidation 
(13, 64, 65). It has been shown that: i) adipocyte-specific Lpin1 knockout mouse models, ii) Lpin1(fld/fld) mice, 
carrying spontaneous inactivation of the Lpin1 gene, and iii) Lpin11Hubr rats with a mutated lipin-1 protein, all 
unambiguously display lipodystrophy (even if each animal model is characterized by different penetrance and 
severity of the pathological phenotype) (1, 2, 7, 14, 24, 53). The single lipin protein orthologue in Drosophila 
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(encoded by dLipin) is also essential for normal fat body development, and for normal lipid accumulation and 
TAG storage in the lipid droplets of the adipocytes (66).  
Although loss of lipin-1 in mouse models leads to manifest lipodystrophy, hepatic steatosis and insulin 
resistance, so far none of these pathological conditions have also been observed in human individuals deficient 
in lipin-1, who have normal adipose tissue distribution and fat weight (27, 28, 32). Instead, we and others 
showed that deleterious LPIN1 mutations cause recurrent severe paediatric clinical episodes of rhabdomyolysis, 
a syndrome consisting in massive breakdown of skeletal muscle fibers, leading to myoglobinuria (27, 29, 32). 
The clinical features of rhabdomyolysis observed in human lipin-1-defective patients are compatible with that 
observed in Lpin1(fld/fld) mice models subjected to specific metabolic stress, in which skeletal muscle myofibrillar 
necrosis was also evident, due to impairment of mitochondrial functions and autophagy (30). 
Until now, a thorough and systematic analysis of human adipose tissue from patients harboring LPIN1 
inactivating mutations was not performed. We established that the WAT tissue from these patients: i) is 
characterized by severely reduced levels of LPIN1 mRNA, lipin-1 protein and PAP activity, without the 
concomitant compensatory increased expression of LPIN2 and LPIN3; ii) does not show any of the typical 
histopathological features associated with lipodystrophy (i.e: hypoplastic development, inflammation, increased 
mixoid stroma, abnormal lipid droplets, abnormal vasculature); iii) shows a moderate reduction of adipocyte 
size, indicative of a possible decreased capacity of fat accumulation in the lipid droplets; iv) has a normal 
qualitative composition of the stored lipids; v) express significantly higher levels of the key positive regulators 
of the adipogenesis SREBF1, PPARG and PGC1A. 
The observation that human adipose tissue in lipin-1 deficient patients can develop fully and store 
neutral lipids normally, can be explained if some specific compensatory phenomena were triggered in human 
adipocytes. In agreement with this hypothesis, here we showed that fat biopsies from lipin-1 defective patients 
express significantly higher levels of SREBP1, PPARG and PGCA1, three pivotal determinants of the 
adipogenesis (64, 67). Also, mesenchymal populations derived from lipin-1-defective patients recapitulate the 
key transcriptional events that characterize the multistep process of adipogenic differentiation. These results 
agree with our previous experimental observations, showing that PPAR/PGC-1α mediated-adipogenesis is 
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increased in human lipin-1-deficient myoblasts (29), and also with our description of an autoptic case of a young 
lipin-1 defective patient with an associated severe cardiac infiltration with adipocytes (68). This would be 
consistent with an increased adipogenesis induced by SREBP1, PPARG and PGCA1 upregulation.  
We established that lipin-1 accounts for the majority of PAP activity in human WAT, and that the 
inactivating mutations are compatible with a normal human adipose tissue differentiation and functions. In 
agreement with this, depletion of lipin-1 by siRNA in the human pre-adipocitic SGBS cell line leads to about 
95% of depletion of PAP activity without impairing adipogenic differentiation and accumulation of neutral lipids 
(31). By contrast to what we observed in WAT of human patients carrying biallelic inactivating mutations in 
LPIN1, repression of lipin-1 in SGBS cells caused a significant reduction of the key adipogenic transcription 
factors PPARG and SREBP1 (31).  
The lipin paralogues lipin-1, -2 and -3 share homologous sequences, and overlapping PAP enzymatic 
functions (9). Lipin-2 and -3 can potentially compensate for the absence of lipin-1 (9, 25, 69). Previous studies 
with 3T3-L1 mouse preadipocyte cells showed that lipin-1 is progressively expressed during differentiation in 
culture (6), and lipin-1 depletion after the initiation of the adipogenesis results in increased expression of lipin-2 
(but not of lipin-3) (26). However, in the present study we showed that the severe deficiency of lipin-1 and of 
PAP activity in human adipose tissue was not compensated by an increased expression of LPIN2 (Fig. 6), and 
LPIN3 expression was never detectable in human adipose tissue of patients or controls (results not shown).  
 Virtually no PAP activity was reported in WAT and in skeletal muscle from lipin-1 deficient 
[Lpin1(fld/fld)] mice (9). These results probably depend on the composition of the PAP assay since adjusting the 
Mg2+ concentration and the pH in the PAP assay revealed that hearts of Lpin1(fld/fld) mice still retain about 15-
20% of the PAP activity of the controls (25), and this was sufficient to sustain normal rates of TAG synthesis 
and β-oxidation in perfused working hearts, even thought there was cardiac dysfunction (25). It was concluded 
that PAP activity is normally present in excess in the mouse cardiac tissue, and that lipins-2 and -3 were able to 
compensate for the complete loss of lipin-1 in the Lpin1(fld/fld)  hearts (25). 
 In the present study we used the same PAP assay used in (25) and found that WAT biopsies from lipin-1 
defective patients displayed, on average, about 13% of the PAP activity of the controls. Consistent with this, we 
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previously showed a severe reduction of the cellular PAP activity in primary myoblasts established from lipin-1 
defective patients carrying different types of LPIN1 mutant alleles (29), but we also observed that all of primary 
myoblasts analyzed sill retained a significant cellular PAP activity (29). We conclude that the significant residual 
PAP activity in WAT of lipin-1 deficient patients (Fig. 4 C) depends on the low (but significant) expression of 
LPIN2 in this tissue (Fig. 6). This is substantiated also by the weak residual band on the Western blots of WAT 
from patients, as shown in Fig. 4 A and B, since the antibody anti-human lipin-1 we used cross reacts with lipin-
2 (see Methods). Using the same antibody anti-lipin-1, a residual weak protein band of about 100 kDa was also 
detected in Western blots of myoblasts established from the patients analyzed in this work (result not shown). 
The expression of lipin-2 in human adipose tissue of patients carrying lipin-1 inactivating mutations could be 
sufficient to sustain a normal TAG synthesis and adipogenesis. This would explain the difference between the 
mouse and human phenotype in absence of a functional lipin-1. 
 Lipin-1 is a multifunctional protein that can regulate lipid metabolism at several levels (5, 10, 11-13). 
Under physiological conditions and in response to increased fatty acid delivery, lipin-1 dependent PAP activity 
can play a specialized role to rapidly increase the esterification of fatty acids into TAG in the adipose tissue, 
whereas the lipin-1 gene regulatory effects (mediated by PGC-1α) appear to be particularly prominent in the 
liver, supporting the hepatic capacity for β-oxidation (FAO) and suppressing the hepatic fatty acid synthesis 
(13).  The evidence that we have presented suggests under homeostatic conditions that the WAT in lipin-1 
defective patients shows a virtually normal metabolic lipid balance, without any evident accumulation of 
unesterified fatty acids (Fig. 5). Possibly, if these patients were challenged by circumstances of increased fatty 
acid delivery (such as fasting, diabetes, a diet rich in fat, alcohol assumption), they would show the symptoms of 
impaired capacity for fatty acid esterification in WAT, with a consequent accumulation of unesterified fatty 
acids. 
Theoretically, LPP activity could compensate the severe PAP defect that is observed in patients. 
However it was shown in Lpin11Hubr rat model of PAP-deficiency, that the compensatory increase of LPP was 
restricted to the sciatic nerve endoneurium, but was not detectable in WAT (24). Also in the Lpin1(fld/fld) mice, no 
significant difference in LPP activity was found in WAT (23). Furthermore, the location of the catalytic site of 
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the LPPs on the outer surface of the plasma membrane, or on the luminal surface of internal membranes, make it 
unlikely that the PA formed during lipid synthesis in the ER could be available directly to the LPPs (70). 
Lipin-1 catalyzes a crucial step in triacylglycerol (TAG) biosynthesis, which agrees with reduced neutral 
lipid storage and accumulation of PA that has been observed in lipin-1 deficient mouse (2, 5, 7, 14, 16, 22-24). 
Analysis of the lipids in muscle of Lpin1(fld/fld) mice showed accumulation of high levels of various phospholipids 
(PL) and unesterfied FA, that could contribute to altered metabolism in lipin-1-deficient muscles (30). Our 
analysis of WAT biopsies revealed that patients carrying inactivating mutations of the LPIN1 gene are not 
characterized by altered relative proportions between TAG and PL, or by altered relative proportion of the long 
chain FA in the TAG, or by abnormal accumulation of unesterified FA or phospholipids (Fig. 5). 
We found a significant, but moderate, reduction in adipocyte size in lipin-1 deficient patients compared 
with normal controls, which could be symptomatic of a reduced capacity for neutral lipid storage in the lipid 
droplets in these patients. However, we cannot completely exclude the possibility that the reduced adipocyte size 
might depend on other confounding factors (age, genetic background, environmental factors, etc.) or adaptations 
of the energy balance linked to muscle alteration in patients. Accumulation of neutral lipids is determined by a 
balance among lipid biosynthesis, lipid hydrolysis and β-oxidation. Therefore, further analysis is required to 
explore the hypothesis that other non-lipin-dependent compensatory pathways, like the monoacylglycerol O-
acyltransferase (MOGAT) pathway (71), or the downregulation of the lipid hydrolysis and FAO, may contribute 
to compensate the deficiency of lipin-1 in human patients. 
In summary, adipose tissue from patients with biallelic LPIN1 inactivating mutations displays a dramatic 
reduction in lipin-1 levels and PAP activity. Nevertheless, the adipose tissue appeared to develop normally, 
without manifest signs of lipodystrophy and with a normal qualitative composition of the storage lipids. The 
overexpression of key adipogenic determinants such as SREBP1, PPARG and PGC1A and the residual PAP 
activity suggest that specific compensatory phenomena should be activated in human adipocytes in the presence 
of lipin-1 depletion. Additional work is required to decipher the exact nature of this compensation program. This 
paper highlights the evidence that human beings and mice can exhibit very important patho-physiological 
differences, despite the very high conservation of the genomes, and despite the high similarity in the 
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transcriptional landscapes, gene regulation machinery and metabolic networks. In particular, the penetrance of 
deleterious mutations in metabolic genes can depend strongly on the activation of compensatory phenomena, 
such as metabolic and genetic regulations, expression of paralogues genes, etc., in association with 
environmental factors. 
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TABLES and TABLES LEGENDS 
 
Table 1 
 
Individual Specimens 
used in 
experiment: 
 
age 
 
sex 
 
LPIN1 mutations 
Nucleotides 
 
LPIN1 mutations 
Amino Acids 
control 1 s.a.t.b. 12 F WT WT 
control 2 s.a.t.b. 15 F WT WT 
control 3 s.a.t.b. 18 M WT WT 
control 4 s.a.t.b. 16 M WT WT 
control 5 s.a.t.b. 4 M WT WT 
control 6 s.a.t.b. 15 M WT WT 
control 7 s.a.t.b. 15 M WT WT 
control 8 skin fibroblasts 
population 
5 F  
WT 
 
WT 
control 9 skin fibroblasts 
population 
 
2.5 
M  
WT 
 
WT 
control 10 skin fibroblasts 
population 
 
8.5 
M  
WT 
 
WT 
lipin-1 deficient 1 s.a.t.b. 5 M c.1162C>T 
c.1162C>T 
p.Arg388X   
p.Arg388X 
lipin-1 deficient 2 s.a.t.b. 5 M c.1441+2T>C 
c.2295-866_2410-30del 
p.Asn417LysfsX22 
p.Glu766_Ser838del 
lipin-1 deficient 3 s.a.t.b. 11 M c.1441+2T>C 
c.2295-866_2410-30del 
p.Asn417LysfsX22 
p.Glu766_Ser838del 
lipin-1 deficient 4 s.a.t.b. 47 M c.1162C>T 
c.1162C>T 
p.Arg388X   
p.Arg388X 
lipin-1 deficient 5 skin fibroblasts 
population 
4 F c.2295-863_2410-27del 
c.2295-863_2410-27del 
p.Glu766_Ser838del 
p.Glu766_Ser838del 
lipin-1 deficient 6 skin fibroblasts 
population 
11.5 F c.1441+2T>C 
c.2295-863_2410-27del 
p.Asn417LysfsX22  
p.Glu766_Ser838del 
Lipin-1 deficient 7 skin fibroblasts 
population 
4 F c.2295-863_2410-27del 
c.921delT 
p.Glu766_Ser838del 
p.Gln308ArgfsX36 
 
Table 1. Characterization of the patients and healthy controls individuals used in the study. 
Legend: s.a.t.b.: subcutaneous adipose tissue biopsy.  
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Table 2 
 
A) Adipocytes diameter (µm): exploratory statistics. 
Group Min. 1st Qu. Median Mean 3rd Qu. Max. 
 
Controls 
(n=5) 
 
 
13.94 
 
 
 
51.74 
 
 
 
70.14 
 
 
 
72.18 
 
 
 
91.92 
 
 
 
153.9 
 
 
Patients 
(n=4) 
 
10.57 
 
 
 
43.93 
 
58.67 
 
61.25 
 
77.81 
 
142.2 
 
 
B) Two-sample Kolmogorov-Smirnov test. 
 D p-value 
Patients (n=4) vs Controls (n=5) 0.174 4.59e-05 (***) 
Patient 1 vs Controls (n=5) 0.204 0.012 (*) 
Patient 2 vs Controls (n=5) 0.147 0.143 
Patient 3 vs Controls (n=5) 0.157 0.092 (*) 
Patient 4 vs Controls (n=5) 0.417 1.102e-13 (***) 
 
Table 2. Histomorphometric analysis of the adipocytes diameters. A: Exploratory statistics for the 
experimentally observed adipocytes diameters. The diameters (expressed in µm) of about 100 adipocytes was 
measured in each histological section derived from 5 normal controls and 4 lipin-1 defective patients, and the 
exploratory statistics were calculated for the entire group of 5 controls and for the entire group of 4 patients. 
Minimum, maximum, 1st quartile, median, 3rd quartile and mean are shown for each group. B: The empirical 
cumulative distribution functions (ECDF) of the adipocytes diameters were calculated for the grouped patients  
(n=4) and the grouped controls (n=5), or, to minimize the possible confounding effect of age on the adipocyte 
size, for each patient and for the grouped controls, as shown in Fig. 3. The two-sample Kolmogorov-Smirnov 
(K-S) non-parametric test was applied to statistically test the null hypothesis that the values observed for the 
grouped patients or for each patient were  drawn from the same CDF of the grouped controls. Patient 1, age 5; 
Patient 2, age 5; Patient 3, age 11; patient 4, age 47. Control 1, age 12; Control 2, age 15; Control 3, age 18; 
Control 6, age 15; Control 7, age 15 (Controls: n=5, mean age: 15; s.d. = 1.9). Significant differences are 
indicated by *, P<0.1; ***, P<0.001. 
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Table 3 
    
  
LCFATAG   C:D 
 
  
16:0 
 
(%) 
 
16:1 
 
(%) 
18:0 
 
(%) 
18:1 
 
(%) 
18:2 
 
(%) 
LPIN1 def. 1 22.82 3.82 6.37 50.03 16.96 
LPIN1 def. 3 25.30 4.91 7.15 49.19 13.45 
LPIN1 def. 4 28.20 3.10 5.90 47.10 15.50 
mean patients ± sd 25.40 ± 2.62 4.00 ± 0.84 6.46 ± 0.65 48.82 ± 1.44 15.33 ± 1.76 
      
Control 3 33.30 4.70 4.90 46.20 10.60 
Control 5 26.36 4.29 8.12 51.69 9.54 
Control 6 25.71 4.92 8.41 51.53 9.43 
mean controls ± sd 29.05 ± 4,28 4.86 ± 0.44 7.01 ± 1.78 48.74 ± 4.06 10.34 ± 1.20 
 
Table 3. Long-chain fatty acids composition of triacylglycerols (LCFATAG) derived from lipin-1 defective 
patients and normal controls. Total lipid extracts were fractionated using a two-phase extraction method (35). 
TAG were separated by TLC as shown in Fig. 3 and LCFATAG analysed by gas chromatography. Data are 
presented for the different C:D (i.e. for the different lipid number, where C is the number of carbon atoms in the 
fatty acid and D is the number of double bonds in the fatty acid) as percent (%) of the total of LCFATAG. Mean 
values ± SD for the LCFATAG (%) of patients and controls are shown for each C:D.	
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Figure 1. Histomorphometrical and ultrastructural analyses of the adipose tissue in patients carrying 
biallelic LPIN1 inactivating mutations. A, B, D and E: microscopic imagines at low (A, D) and high (B and E) 
magnification of semi-thin sections stained with azur B-methylene blue, representative of subcutaneous adipose 
tissue biopsies derived from normal control individuals (A, B) and from lipin-1 defective patients (D, E), from 
biopsies fixed in glutaraldehyde and treated as indicated in the Methods section. No signs of lipodistrophy or 
perturbation of the adipose tissue morphology and organization were observed in histological sections from 
lipin-1 defective patients (D, E) compared with controls (A, B). Scale bars in A and D: 25 µm; scale bars in B 
and E: 2.5 µm. C and F: transmission electronic microscopy (TEM) microphotographs. No signs of alteration in 
the adipocyes ultrastructure were observed in lipin-1 defective patients. Scale bars in C and F: 200 nm. Legend: 
m, mitochondria; coll, extracellular fibrillar collagen; ld, lipid droplet; pm, plasmamembrane; ldm, membrane of 
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the lipid droplet. The experiment shown was repeated three times using biopsies derived from three independent 
lipin-1 defective patients and from three independent control individuals, and gave similar results.  
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Figure 2. Histomorphometrical analysis of the adipose tissue in patients carrying biallelic LPIN1 
inactivating mutations. Histological sections from subcutaneous adipose tissue biopsies derived from lipin-1 
defective patients and from controls were immunostained with an anti-perilipin antibody; the nuclei were 
counterstained with DAPI. The sections were subjected to immunoflourescence microscopy. Representative 
immunofluorescent image for a control individual (A-C) and for a lipin-1 defective patient (D-F) are shown. 
Perilipin cellular distribution and relative abundance did not show any significant difference in the adipose tissue 
from lipin-1-deficient individuals, when compared to normal controls. Anti-perilipin antibody, green; DAPI 
staining of the nuclei, blue; scale bars = 25 µm. The experiment was repeated using biopsies from three 
independent lipin-1 defective patients and four control individuals, and gave similar results. G: Ratio total 
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number of adipocyes/total number of cells (estimated by nuclei staining). For each biopsy, the number of 
perilipin-positive adipocytes and of the DAPI-positive nuclei was counted in 5 random microscopic fields; the 
dots indicate the average ratios for each biopsy. Bars represent the mean from four independent control 
individuals and three independent lipin-1 defective patients. Student's t-test and the Mann-Withney test were 
used for controls versus lipin-1 deficient samples comparison. ns, not significant. 
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Figure 3. Histomorphometric analysis of the adipocytes diameters in patients carrying biallelic LPIN1 
inactivating mutations. The diameter (expressed in µm) of about 100 adipocytes was measured in each 
subcutaneous adipose tissue histological section, from 5 normal controls and 4 lipin-1 deficient patients. Control 
1, age 12; Control 2, age 15; Control 3, age 18; Control 6, age 15; Control 7, age 15; Patient 1, age 5; Patient 2, 
age 5; Patient 3, age 11; Patient 4, age 47 (see Table 1). The controls were highly homogeneous in age (controls: 
n=5, mean age: 15; s.d. = 1.9), and treated as a group. Two different statistical approaches were used to 
minimize the possible confounding effect of age on the adipocytes size (see Results section and Table 2). A: 
histograms of the frequency distribution of the adipocytes diameter for each control and each patient. B: 
histogram of the frequency distribution of the adipocytes diameter for the entire group of controls (n=5) and the 
entire group of patients (n=4). C: empirical cumulative distribution functions (ECDF) of the adipocytes 
diameters, for the entire  group of 5 controls (red), the entire group of patients (blue), and the whole sample 
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(controls + patients) (black). These experiments (see Results section and the accompanying Table 2) show a 
significant decrease in the adipocyte size in the patients compared with normal controls. 
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Figure 4. Lipin-1 protein levels and PAP activity in adipose tissue in patients carrying biallelic LPIN1 
inactivating mutations. A: Western blotting analysis of lipin-1 protein levels. 60 µg of total protein extracts 
from adipose tissue biopsies from three patients and from four normal controls were subjected to WB analysis, 
with the indicated specific antibodies. Two samples of breast adipose tissue (B1 and B2) were also used as 
controls, due to paucity of the biopsied subcutaneous WAT controls. Legend: P1 and P4: subcutaneous WAT 
from Patient 1 and Patient 4 (see Table 1), carrying the LPIN1 homozygous early stop mutations 
p.Arg388X/p.Arg388X; P3, subcutaneous WAT from Patient 3 (see Table 1) carrying the LPIN1 heterzygous 
mutations p.Asn417LysfsX22/p.Glu766_Ser838del (i.e. an early stop mutation and a C-terminal deletion); C6 
and C7, subcutaneous WAT from normal individuals (Control 6 and Control 7, see Table 1); B1 and B2:  control 
WAT from adult breast, obtained from two normal individuals, respectively 53 and 56 years old, subjected to 
reduction mastoplasty (see Methods). B: Densitometric analysis of the relative lipin-1 protein levels, equalized 
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for tubulin expression; protein levels were obtained from the WB in (A), and shown as means ± S.D. of three 
(patients) or of four (controls) independent determinations. C: PAP activity for the same samples shown in (A). 
The values in panels B and C for the controls adipose tissue showed that that both measures were tightly grouped 
for the subcutaneous WAT controls (C6 and C7) and for the breast WAT controls (B1 and B2), and did not 
depend on the anatomical location of the biopsied samples. In B and C significant differences are indicated by 
**, P<0.01 (Student's t-test). 
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Figure 5. Qualitative lipid analysis of adipose tissue from lipin-1 defective patients and normal controls.  
A-D: representative high performance TLC of the hexane and the ethanol total lipid extraction fractions (35) 
obtained from subcutaneous WAT biopsies from a normal control individual (A and B) and from a lipin-1 
defective patient (C and D). Similar experiments were repeated using adipose biopsies from five control 
individuals and from four independent lipin-1 defective patients, obtaining analogous results. A and C: neutral 
lipids TLC separation. B and D: polar lipids (PL) TLC separation. Legend TAG: triacylglycerols; FFA: 
unesterified (free) fatty acids; DAG: diacylglycerol; PE: phosphatidylethanolamine; PC: phosphatidylcholine; 
PS: phosphatidylserine; PI: phosphatidylinositol; PA: phosphatidate. As shown in A and C, the hexane 
extraction phases: i) contained the whole TAG, ii) contained a part of sterols and DAG, iii) presented negligible 
amounts of unesterified FA, and iv) were devoid of PL. As shown in B and D, the ethanol extraction phases: i) 
Neutral Lipids  
Fractionation A  
TAG 
start 
sterols 
front 
DAGs 
Polar lipids 
FFA 
Neutral Lipids 
Polar Lipids  
Fractionation B 
PA 
front 
start 
Control 
FFA 
DAGs 
TAG 
start 
Neutral Lipids  
Fractionation 
sterols 
Polar lipids 
front 
C  
D 
Lipin-1 defective patient 
PA 
front Neutral Lipids 
start 
Polar Lipids  
Fractionation 
500 
1,000 
1,500 
2,000 
2,500 
3,000 
3,500 
0 
4,000 
LC
FA
TA
G
 / 
LC
FA
PL
 
n.s. E 
PC 
PS + PI 
PE 
PC 
PS + PI 
PE 
49		
contained the totality of PL; ii) contained the remaining part of sterols, and iii) presented only traces of TAG, 
and negligible amounts of unesterified FA. E: ratio  LCFATAG/LCFAPL. The relative abundance of TAG and PL 
in the total lipid extracts from each biopsy, was determined by the internal ratio LCFATAG/LCFAPL, 
corresponding, to the mass in µg of long-chain fatty acids derived from TAG (LCFATAG) divided for the mass in 
µg of LCFA derived from whole polar lipids PL (LCFAPL). The silica gel zones of in the TLC corresponding to 
TAG and PL were scrapped from the respective TLC plate, and the lipids analyzed by gas-chromatography (GC-
FID). Bars represent the means of the ratios LCFATAG/LCFAPL from five independent control individuals (mean 
= 1,959) and from four independent lipin-1 defective patients (mean = 2,355). Student's t-test was used for 
controls versus lipin-1 deficient comparison. ns, not significant. 
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Figure 6. Expression analysis of key adipogenic genes in fat biopsies from lipin-1 defective patients. 
Subcutaneous adipose tissue biopsies from four independent lipin-1 defective patients and four independent 
control (healthy) individuals were collected and total RNA extracted. First-strand cDNA was generated from 
1 µg of total RNA, to perform real-time PCR using specific primers for PPARG, SREBF1, PGCA1, LPIN1, 
LPIN2 and ACTB. Expression data were normalized using ACTB as housekeeping gene. Relative expression 
values are expressed as mean values (bars). ns, not significant; *, P<0.05;  **, P<0.01 (Student's t-test). 
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Figure 7. Human dermal primary fibroblasts populations derived from patients carrying biallelic LPIN1 
inactivating mutations or from control individuals express MSC-specific cell surface markers. Human 
dermal primary fibroblasts populations derived from normal control (healthy) individuals or from lipin-1 
defective patients (Table 1) were cultured until confluence in GM. After one day of confluence, cells were 
harvested, total RNA extracted and first-strand cDNA generated from 1 µg of total RNA, to perform real-time 
PCR using specific primers for VCAM-1 (CD106), MCAM (CD146), ITGA11, MME (CD10) and DPP4 (CD26). 
Expression data were normalized using ACTB as housekeeping gene. Relative expression values are expressed as 
means values ± SD, and shown in logarithmic scale. 
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Figure 8. Human fibroblasts populations derived from patients carrying biallelic LPIN1 inactivating 
mutations can be induced to adipogenic differentiation. Human dermal primary fibroblasts populations 
derived from normal control (healthy) individuals or from lipin-1 defective patients (see Table 1) were cultured 
until confluence in GM. Cells were then shifted to adipogenic differentiation medium, DM (+), containing 
insulin, DXM, IBMX and indometacin, or left in GM (-). After 4, 8 or 12 days in DM cells were harvested, the 
total RNA extracted and the first-strand cDNA generated from 1 µg of total RNA, to perform real-time PCR 
using specific primers for PPARG, FASN and PGC1A. Expression data were normalized using actin beta (ACTB) 
as housekeeping gene. Relative expression ± SD is shown in the histograms. 
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